GT200800225A - Metodo para inhibir la cinasa del c-kit - Google Patents

Metodo para inhibir la cinasa del c-kit

Info

Publication number
GT200800225A
GT200800225A GT200800225A GT200800225A GT200800225A GT 200800225 A GT200800225 A GT 200800225A GT 200800225 A GT200800225 A GT 200800225A GT 200800225 A GT200800225 A GT 200800225A GT 200800225 A GT200800225 A GT 200800225A
Authority
GT
Guatemala
Prior art keywords
kit
inhibiting
cell
treat
disorders
Prior art date
Application number
GT200800225A
Other languages
English (en)
Inventor
Carl R Illig
Shelley K Ballentine
Jinsheng Chen
Sanath K Meegalla
Mark J Wall
Kenneth J Wilson
M Jonathan Rudolph
Renee L Desjarlais
Carl L Manthey
Christopher J Molloy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200800225A publication Critical patent/GT200800225A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

UN MÉTODO PARA REDUCIR O INHIBIR LA ACTIVIDAD DE LA CINASA DEL C-KIT EN UNA CÉLULA O UN SUJETO, Y EL USO DE TALES COMPUESTOS PARA PREVENIR O TRATAR EN UN SUJETO UN TRASTORNO PROLIFERATIVO CELULAR Y/O TRASTORNOS RELACIONADOS CON EL C-KIT, UTILIZANDO UN COMPUESTO DE LA PRESENTE INVENCIÓN DE FÓRMULA (I) O UN SOLVATO O HIDRATO, TAUTÓMERO O SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO; LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA ADEMÁS A MÉTODOS PARA TRATAR CONDICIONES TALES COMO CÁNCERES Y OTROS TRASTORNOS PROLIFERATIVOS CELULARES. T2008
GT200800225A 2006-04-20 2008-10-21 Metodo para inhibir la cinasa del c-kit GT200800225A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79347106P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
GT200800225A true GT200800225A (es) 2009-05-15

Family

ID=38625740

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800225A GT200800225A (es) 2006-04-20 2008-10-21 Metodo para inhibir la cinasa del c-kit

Country Status (22)

Country Link
EP (2) EP2015748B1 (es)
JP (1) JP5595727B2 (es)
KR (1) KR101448052B1 (es)
CN (2) CN101610768B (es)
AU (1) AU2007240400B2 (es)
BR (1) BRPI0710542B8 (es)
CA (1) CA2649755C (es)
CO (1) CO6382175A2 (es)
CR (1) CR10450A (es)
EA (1) EA016611B1 (es)
EC (1) ECSP088842A (es)
ES (2) ES2458291T3 (es)
GT (1) GT200800225A (es)
HK (1) HK1124766A1 (es)
IL (1) IL194846A (es)
MX (1) MX2008013528A (es)
MY (1) MY147226A (es)
NO (1) NO342001B1 (es)
NZ (1) NZ572200A (es)
SG (1) SG171592A1 (es)
WO (1) WO2007124369A2 (es)
ZA (1) ZA200809874B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5944503B2 (ja) 2011-07-27 2016-07-05 エービー サイエンス 選択的プロテインキナーゼ阻害剤
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
AR096984A1 (es) 2013-07-22 2016-02-10 Actelion Pharmaceuticals Ltd Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona
US10053457B2 (en) 2015-01-15 2018-08-21 Idorsia Pharmaceuticals Ltd. Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
CN105753770A (zh) * 2015-05-27 2016-07-13 上海佐林生物医药有限公司 蛋白激酶抑制剂制备方法、中间体、制备方法及应用
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332948T2 (de) 1992-03-05 2003-11-27 Univ Texas Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
ES2223705T3 (es) 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
IL166528A0 (en) * 2002-08-02 2006-01-15 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
BRPI0415467A (pt) * 2003-10-23 2006-12-19 Ab Science compostos de 2-aminoariloxazol para o tratamento de doenças
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
NZ548884A (en) * 2004-01-30 2010-06-25 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
EA013250B1 (ru) * 2004-10-22 2010-04-30 Янссен Фармацевтика, Н.В. Ингибиторы c-fms киназы
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US7795279B2 (en) * 2005-10-18 2010-09-14 Janssen Pharmaceutica Nv Method of inhibiting FLT3 kinase
JP5089681B2 (ja) * 2006-04-20 2012-12-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤としての複素環式化合物
EP2016074B1 (en) * 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
AU2006342509A1 (en) * 2006-04-20 2007-11-01 Janssen Pharmaceutica, N.V. c-fms kinase inhibitors

Also Published As

Publication number Publication date
EA016611B1 (ru) 2012-06-29
BRPI0710542B1 (pt) 2021-01-12
CA2649755C (en) 2014-12-02
AU2007240400B2 (en) 2013-08-22
SG171592A1 (en) 2011-06-29
CA2649755A1 (en) 2007-11-01
ES2389678T3 (es) 2012-10-30
WO2007124369A2 (en) 2007-11-01
ZA200809874B (en) 2010-02-24
WO2007124369A3 (en) 2008-03-06
MX2008013528A (es) 2008-10-29
CN102670605A (zh) 2012-09-19
CR10450A (es) 2009-02-23
EP2015748A2 (en) 2009-01-21
KR101448052B1 (ko) 2014-10-07
KR20080111545A (ko) 2008-12-23
AU2007240400A1 (en) 2007-11-01
ES2458291T3 (es) 2014-04-30
CN101610768A (zh) 2009-12-23
BRPI0710542A2 (pt) 2012-06-05
ECSP088842A (es) 2008-11-27
EP2397138B1 (en) 2013-12-11
JP5595727B2 (ja) 2014-09-24
NO342001B1 (no) 2018-03-12
EP2397138A1 (en) 2011-12-21
HK1124766A1 (en) 2009-07-24
BRPI0710542B8 (pt) 2021-05-25
IL194846A (en) 2015-07-30
EA200870454A1 (ru) 2009-04-28
CO6382175A2 (es) 2012-02-15
NZ572200A (en) 2011-09-30
MY147226A (en) 2012-11-14
CN101610768B (zh) 2012-03-21
CN102670605B (zh) 2015-07-29
IL194846A0 (en) 2009-08-03
EP2015748B1 (en) 2012-07-04
JP2009534418A (ja) 2009-09-24
NO20084892L (no) 2009-01-06

Similar Documents

Publication Publication Date Title
GT200800225A (es) Metodo para inhibir la cinasa del c-kit
SV2008002880A (es) Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms ref. prd2549sv
CR20200441A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CL2013002870A1 (es) Sal diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida; método de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento o profilaxis del cáncer.
CL2011000480A1 (es) Compuestos derivados de amino-1,2,4-triazolo[1,5-a]piridina sustituidos, inhibidores de quinasa; composicion farmaceutica; y su uso para el tratamiento o prevencion de condiciones inflamatorias, inmunologicas, autoinmunes, alergicas, reumaticas, tromboticas, cancer, infecciones, padecimientos neurodegenerativos, entre otras.
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
UA104731C2 (ru) Ингибиторы р38 мар-киназ
ME00936B (me) Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
TW200614990A (en) Methods for preparing indazole compounds
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
IL210071A0 (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
CL2009001058A1 (es) Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
PH12016501073B1 (en) Tropomyosin-related kinase (trk) inhibitors
HK1138572A1 (en) Aminopyrimidines useful as inhibitors of protein kinases
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
ZA202205900B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
CL2011003052A1 (es) Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras.
ECSP11011172A (es) Derivados de tieno [3,2-c]piridina como inhibidores de quinasas para el uso en el tratamiento del cáncer.
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
PA8843901A1 (es) INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR